Lilly Posts Profit, Raises Forecasts Wednesday, October 21, 10:11 AM ET
Eli Lilly (NYSE:LLY) posted a third quarter profit of $941.8 million, or 86 cents per share, as compared to a loss of $465.6 million, or 43 cents per share, in the same quarter last year. Last year’s quarter included legal costs related to the government investigation of Zyprexa.
Excluding restructuring costs and other items, Lilly earnings totaled $1.20 per share this quarter, better than analysts expected.
Among top performers in the quarter, sales of Lilly’s standout anti-psychotic drug Zyprexa were up 3 percent to $1.2 billion, sales of cancer treatment Alimta rose 47 percent to $462 million. Sales of these drugs and others drove revenue higher by 7 percent to $5.56 billion.
Lilly is now looking for a full-year adjusted profit in a range of $4.30 to $4.40 per share, as compared to a previous forecasts of $4.20 to $4.30 per share.
Stage Stores Boosts Dividend 50% Friday, August 27, 11:42 AM ET, by Market News Video Staff This morning, Stage Stores, Inc. (SSI) declared its quarterly dividend of 7.5 cents per share, ...
HP's Revised Bid Weighs on IYW Friday, August 27, 11:09 AM ET, by Market News Video Staff Before the markets opened on Friday, Hewlett Packard announced that it had raised its bid ...
Intel Warns On 3Q Sales Friday, August 27, 10:59 AM ET, by Market News Video Staff Intel (INTC) warned on Friday that sales for the current quarter could come in lighter ...
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.